作者: Neil Binkley , Mark G. Martens , Stuart L. Silverman , Richard J. Derman , Maria Greenwald
DOI: 10.1097/SMJ.0B013E31819ED0DD
关键词:
摘要: Objective: This subanalysis of CURRENT, an open-label, 6-month, multicenter study, assesses changes in gastrointestinal (GI) tolerability with once-monthly oral ibandronate women who switched from once-weekly bisphosphonates and had reported GI symptoms their previous weekly bisphosphonate regimen. Methods: Postmenopausal currently taking a to 150 mg monthly ibandronate. At the start treatment phase after 6 months therapy, all participants completed Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q™), validated instrument consisting four domains: convenience, satisfaction, quality life, side effects. assessed those at baseline effects domain OPSAT-Q™ change satisfaction stomach upset within 48 hours screening. Results: Of baseline, >60% improvement heartburn or acid reflux switching Further, >70% improvements (excluding reflux). screening (n = 89), >80% improved overall compared baseline. Monthly was generally well tolerated. Conclusion: A majority experienced issues transitioning for months.